Board of Directors

The BioCanRx Board of Directors is responsible for ensuring financial accountability, scientific excellence, knowledge exchange and operational efficiency.

Committed to changing the face of cancer treatment

The board approves policies and procedures consistent with the goals and mission of the network. It also determines the mandate, membership, authority and makeup of committees.

The Board provides leadership and direction to BioCanRx so that it remains on target with respect to its strategic plan and commitments.

Members of the board

Russell Williams

Chair, Board of Directors

Dr. John Bell

Scientific Director at BioCanRx, Senior Scientist at The Ottawa Hospital, Professor at uOttawa

Dr. Josée Brisebois

Executive Consultant, Biopharma & Health Sciences Sectors

Dr. David Poon

Co-Founder, Head of Business DCx Biotherapeutics

Doreen Hume

Partner, Audit & Assurance, Deloitte Canada

Dr. John Stagg

Director at Rosalind and Morris Goodman Cancer Institute
McGill University

Antonia Palmer

Co-Founder at Ac2orn: Advocacy for Canadian Childhood Oncology Research Network

Brigette Kocijancic

ABC, PROSCI Certified Global Communications & Change Management Consultant

Mỹ Dang

Director of Regulatory Affairs, Innomar Strategies

Sebastien Beauchamp

LL.M, MBA, ICD.D Vice-President, Government Relations and Corporate Development, Dynacare

Dr. Jumai Abioye

Founder and CEO PanAccess Innovations Inc.

EX-OFFICIO MEMBERS (NON-VOTING)

Dr. Stéphanie Michaud

President and CEO, BioCanRx Secretary, Board of Directors